PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARα) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.
Bibliographic record
Abstract
TPS4214 Background: PPARα is a fatty acid ligand-activated transcription factor that regulates genes involved in fatty acid oxidation (FAO), angiogenesis, and inflammation. In HCC and other tumor types, PPARα signaling promotes tumor growth and also modulates the tumor immune microenvironment to suppress antitumor immunity. Amezalpat (TPST-1120) is an investigational PPARα antagonist that inhibits FAO, targeting the bioenergetic requirements of cancer cells and restoring anticancer immune pathways. HCC has the highest PPARα expression of any major tumor type. In preclinical studies of HCC, including ß-catenin activated disease, amezalpat exhibits anti-cancer activity as a single agent and demonstrates complementary efficacy in combination with PD-L1 and VEGF inhibitors. In an ongoing global randomized Phase 1b/2 study in pts with unresectable or mHCC not previously treated with systemic therapy, amezalpat in combination with atezolizumab + bevacizumab (TPST-AB) was tolerable and was associated with a clinically meaningful improvement in multiple efficacy endpoints, including overall survival (OS) and confirmed objective response rate (ORR), compared to AB alone. Here we describe a follow-up pivotal Phase 3 study to evaluate the safety and efficacy of TPST-AB vs Pbo plus AB (Pbo-AB) in pts with unresectable or mHCC (NCT06680258). Methods: This Phase 3, global, randomized, double-blind study will enroll ~740 pts with unresectable or mHCC. Key eligibility criteria include no prior systemic therapy (prior locoregional therapy allowed), ECOG PS 0-1, Child-Pugh Class A, and measurable disease by RECIST v1.1; pts with fibrolamellar/sarcomatoid HCC, mixed cholangiocarcinoma/HCC, and untreated active HBV are not eligible. Pts will be randomized 1:1 to receive oral amezalpat 600 mg or Pbo twice daily along with the approved doses of atezolizumab and bevacizumab every 3 weeks, until unacceptable toxicity or loss of clinical benefit. Randomization will be stratified by geographic region (Asia excluding Japan vs rest of world), macrovascular invasion and/or extrahepatic spread (y/n), baseline α-fetoprotein ( < 400 vs ≥400 ng/mL), and baseline ECOG PS (0 vs 1). The primary efficacy endpoint is OS. Key secondary efficacy endpoints include progression-free survival and ORR (RECIST v1.1). Exploratory analyses will include outcome by PD-L1 expression and ß-catenin mutational status. Interim analyses for futility (30% OS events) and efficacy (70% OS events) are planned. Findings of this pivotal study will inform the efficacy and safety profile of amezalpat added to AB vs AB alone in pts with unresectable or mHCC not previously treated with systemic therapy. Clinical trial information: NCT06680258 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.003 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.003 | 0.003 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.003 | 0.003 |
| Insufficient payload (model declined to judge) | 0.010 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".